TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2478049
Drug: PCA +
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA + BI with oxymorphone (0.1 mg/hour, n = 16)
Study: 29493100
Drug: Mitiglinide 10
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 10 mg/voglibose 0.2 mg three times daily for 3 days
Study: 29493100
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 mg once daily for 3 days
Study: 27607411
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate+sulfasalazine+hydroxychloroquine with prednisolone)
Study: 27607411
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with anti-TNF induction (infliximab)
Study: 27607411
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with placebo
Study: 23282652
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for allergic rhinitis
Study: 23282652
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for asthma associated with rhinitis
Study: 23282652
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for atopic dermatitis, latex allergy, and hymenoptera hypersensitivity
Study: 12719883
Drug: Saline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline + furosemide (40 mg after hydration)
Study: 12719883
Drug: Saline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline + mannitol (50 g mixed with cisplatin)
Study: 8859177
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository (50 mg) administered once or twice daily for 4 or 8 weeks
Study: 8859177
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository (50 mg)
Study: 1536727
Drug: Cyclosporin 6
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 6 mg/kg body wt. per day for 3 months and tapering doses over the next 3 months
Study: 1536727
Drug: Chlorambucil at
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil at a cumulative dose of 8 mg/kg body wt.
Study: 6097125
Drug: Cefmenoxime (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmenoxime (0.5 to 1 g every six hours)
Study: 6097125
Drug: Cefoxitin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1 to 2 g every six hours)
Study: 25461792
Drug: Wait-list condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list condition (W-L)
Study: 17704023
Drug: n‐3 PUFA/gamma‐CD
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA/gamma‐CD complex (660 mg EPA + 280 mg DHA/day)
Study: 17704023
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (capsules containing essentially no n‐3 PUFA)
Study: 12045164
Drug: Aspirin 1.2
Normalized name: Aspirin 1.2 GM Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1.2 g orally 2 hours before vaccination
Study: 12045164
Drug: Local intrabrachial
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local intrabrachial aspirin 10 mg/min for 15 minutes
Study: 2021561
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (test group, N=17)
Study: 29663291
Drug: Apatinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (oral administration)
Study: 12706704
Drug: Trivalent live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent live, cold‐adapted influenza virus vaccine (CAIV‐T) co-administered with trivalent inactivated influenza virus vaccine (TVV)
Study: 12706704
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza virus vaccine (TVV) and placebo (TP)
Study: 1318765
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (group 1, 54 volunteers) at 0, 1, and 2 months
Study: 1318765
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (group 2, 50 volunteers) at 0, 1, and 6 months
Study: 29514524
Drug: Onion extract
Normalized name: Onion Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion extract gel
Study: 24964176
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg co-administered with steady-state erythromycin in subjects with mild or moderate RI
Study: 24964176
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg co-administered with steady-state erythromycin in subjects with moderate RI
Study: 24964176
Drug: Rivaroxaban administered
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban administered alone in RI subjects
Study: 24964176
Drug: Rivaroxaban co-administered
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban co-administered with steady-state erythromycin in NRF subjects
Study: 20198713
Drug: Pardoprunox (9‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pardoprunox (9‐45 mg/d, mean dose 23.8 mg/d)
Study: 18302208
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with clinical management (PHT-CM)
Study: 18427286
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (EACA) 5 g IV
Study: 15307936
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone replacement therapy (levothyroxine)
Study: 3307366
Drug: Digoxin plus
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin plus nadolol (titrated from 20 to 120 mg daily)
Study: 30661836
Drug: HydroVax-001 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HydroVax-001 (1 mcg dose)
Study: 30661836
Drug: HydroVax-001 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HydroVax-001 (4 mcg dose)
Study: 27092472
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy plus intravenous tPA administration
Study: 22350679
Drug: 100 mcg
Normalized name: Levo-T 100 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg of HFA‐BDP twice daily
Study: 22350679
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg of HFA‐BDP twice daily
Study: 22350679
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (25 mg/day)
Study: 20212073
Drug: High-dose niacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose niacin 2000 mg plus lovastatin 40 mg
Study: 20212073
Drug: Low-dose niacin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose niacin 1000 mg plus lovastatin 40 mg
Study: 16375657
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GbE) at daily doses of 120 mg
Study: 16375657
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GbE) at daily doses of 240 mg
Study: 1102484
Drug: Ara‐A ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ara‐A ointment
Study: 1102484
Drug: IDU ointment
Normalized name: IdU
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDU ointment
Study: 31174526
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily with aspirin 81 mg
Study: 31174526
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily without aspirin
Study: 21550027
Drug: Amolimogene (microparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amolimogene (microparticle encapsulated pDNA vaccine)
Study: 19301724
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) with 0.125% levobupivacaine and morphine 0.0125 mg/ml (4 ml/hr)
Study: 19301724
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve block (CFNB) with 0.125% levobupivacaine (8 ml/hr)
Study: 17201996
Drug: R,S‐citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: R,S‐citalopram (20 mg)
Study: 17201996
Drug: S‐citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐citalopram (10 mg)
Study: 15170981
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) and l-leucovorin (l-LV) given monthly (arm A)
Study: 15170981
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) and l-leucovorin (l-LV) given every 2 months (arm B)
Study: 11408900
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (25 mg) injected once per week for 5 weeks
Study: 11408900
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg) injected once per week for 5 weeks
Study: 11408900
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (SH and steroid)
Study: 2892862
Drug: Prazosin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin administration
Study: 26733057
Drug: Ovaleap® (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovaleap® (150 IU/day for 5 days, then dose-adjusted up to 450 IU/day)
Study: 26733057
Drug: Gonal-f® (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonal-f® (150 IU/day for 5 days, then dose-adjusted up to 450 IU/day)
Study: 25069431
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or tianepine with cognitive-behavioral therapy, supportive therapy, or psychodynamic therapy
Study: 21627399
Drug: Turmeric supplementation
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric supplementation (500 mg per capsule, 3 capsules daily for 2 months)
Study: 21627399
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch capsules identical in colour and size)
Study: 10765039
Drug: Intravenous cefotiam
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefotiam dihydrochloride (CTM) 2 g on induction of anesthesia
Study: 10765039
Drug: Oral cefpodoxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefpodoxime proxetil (CPDX-PR) 100 mg twice daily from day 0 to day 2
Study: 1321542
Drug: 1.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg.kg‐1 suxamethonium preceded by 10 mg gallamine
Study: 6376208
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg/triamterene 50 mg once-daily oral doses
Study: 6376208
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg alone
Study: 31810850
Drug: Vacuum-assisted closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-assisted closure (VAC) therapy
Study: 26559710
Drug: Daily changes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily changes in MVPA
Study: 19884268
Drug: Nonpharmacological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological treatments
Study: 17572579
Drug: Evolence30 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolence30 (30 mg/ml)
Study: 12137881
Drug: Gonadotropin therapy
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin therapy (three cycles of urinary or recombinant gonadotropins)
Study: 10981089
Drug: Various classes
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various classes of blood pressure-lowering agents
Study: 2206033
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg once a day with the morning meal (qam)
Study: 2206033
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg once a day with the evening meal (qpm)
Study: 2206033
Drug: Lovastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 80 mg qpm
Study: 2646895
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg twice daily
Study: 388220
Drug: Prednisone (alternate-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (alternate-day treatment for at least eight weeks)
Study: 29411238
Drug: Home hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home hospital care (nurse and physician home visits, intravenous medications, continuous monitoring, video communication, point‐of‐care testing)
Study: 27475700
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel containing chitosan, 0.2% chlorhexidine, allantoin and dexpanthenol applied 10 ml three times a day for 10 days
Study: 24608624
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir for 1 week
Study: 18806028
Drug: Closed-loop control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop control system for propofol administration
Study: 15577823
Drug: Tacrolimus (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.1 mg/kg)
Study: 11379646
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic (Group II)
Study: 11379646
Drug: Intravenous opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioid (Group III)
Study: 9249783
Drug: Nitrendipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (2 x 5 mg daily for normotensive patients; 2 x 10 mg to 2 x 20 mg daily for hypertensive patients)
Study: 8491391
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate 480 mg/day plus amoxycillin from days 1 to 7 and tinidazole from days 8 to 14
Study: 8491391
Drug: Sucralphate 4
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralphate 4 g/day
Study: 2891631
Drug: Laparoscopic fulguration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic fulguration of endometriotic implants (Group A)
Study: 2891631
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group B) - implants left intact
Study: 27677562
Drug: Urate levels
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urate levels equal to or above the median (5.1 mg/dl)
Study: 22300367
Drug: Curcumin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (2 g)
Study: 22300367
Drug: Sulphasalazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (100 µg or 2 g) alone
Study: 19563327
Drug: Branemark implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Branemark implant system (two-stage screw type)
Study: 17993763
Drug: Trandolapril 0.5
Normalized name: trandolapril 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 0.5 mg qd
Study: 11605101
Drug: Alcohol (4.35+/‐0.53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (4.35+/‐0.53 g/kg per week)
Study: 9481347
Drug: Whirlpool therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whirlpool therapy
Study: 8038616
Drug: 5% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% human serum albumin (0.01 ml/kg)
Study: 20796082
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD)
Study: 20796082
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD)
Study: 19327226
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program intervention (6-week program, weekly sessions lasting 1 hour each)
Study: 17449497
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin to maintain blood glucose <10 mmol/l
Study: 17449497
Drug: 200 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g/day of glucose infusion (control group)
Study: 17449497
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (200 g/day of glucose infusion)
Study: 11477965
Drug: Vi polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi polysaccharide vaccine (30 micrograms)
Study: 2483018
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of dextran
Study: 30694077
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol (4 mg/d) plus vaginal progesterone (90 mg, 2×1/day)
Study: 30694077
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (90 mg, 2×1/day) alone
Study: 25499165
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (maintaining haemoglobin level at 100 g/L or higher)
Study: 25499165
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfusion when haemoglobin level lower than 80 g/L or symptoms of anaemia)
Study: 19592630
Drug: Metformin, pioglitazone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, pioglitazone, and glyburide (oral group)
Study: 17242671
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (platin-based chemotherapy)
Study: 17242671
Drug: Platin-based chemotherapy
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platin-based chemotherapy
Study: 17242671
Drug: Modified schedules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified schedules or attenuated dose of platin-containing chemotherapy
Study: 11194113
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (CrS, 20 g x d(‐1) of Cr)
Study: 27188901
Drug: HMB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB (3 g · day(‐1))
Study: 23021204
Drug: Radium-223 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 (50 kBq/kg, 4 injections every 4 weeks)
Study: 11434648
Drug: Arginine-enriched formula
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine-enriched formula (6.3 g/L)
Study: 7851710
Drug: Beta-adrenergic treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic treatment
Study: 2572261
Drug: xamoterol treatment
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol treatment
Study: 31961963
Drug: Tadalafil +
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil + Mirabegron (5 mg/50 mg/day)
Study: 31961963
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg/day)
Study: 20835873
Drug: Transdermal granisetron
Normalized name: granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal granisetron (GTDS), one patch for 7 days
Study: 20835873
Drug: Oral granisetron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral granisetron, 2 mg/day for 3-5 days
Study: 12601675
Drug: WS(R) 1340
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS(R) 1340 (90 mg peppermint oil)
Study: 12601675
Drug: WS(R) 1520
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS(R) 1520 (50 mg caraway oil)
Study: 30762399
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Therapy for Cancer‐Related Insomnia (BBT‐CI)
Study: 30077640
Drug: Pemafibrate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate (0.4 mg/d, twice daily for 4 weeks)
Study: 21264453
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin A (CsA) 2.5 mg/kg
Study: 21264453
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin A (CsA)
Study: 17199455
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (3-month treatment with a 1-month taper)